Drugs in Dev. Pulmonary/Respiratory Diseases
Undisclosed
Germany 
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Diseases, Interstitial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2022
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treprostinil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Diseases, Interstitial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Diseases, Interstitial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2019
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Details : Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Bronchiectasis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 22, 2016
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 03, 2014
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riociguat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Details : Riociguat is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2013
Lead Product(s) : Riociguat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
